Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a pharmaceutical company incorporated in 2000 with its headquarters located in Basel, Switzerland. The company focuses on the development and commercialization of pharmaceutical products, with a particular emphasis on anti-infectives, including antifungal and antibiotic treatments, and oncology for cancer therapy. Basilea's prominent brands are Cresemba® (isavuconazole), used to treat invasive aspergillosis and mucormycosis, and Zevtera®/Mabelio® (ceftobiprole), indicated for severe bacterial infections. The company markets its products internationally, with a notable presence in Europe and the United States. It also has partnerships enabling product distribution in Asia, the Middle East, and Latin America, though the significance of these countries to Basilea's sales may shift with changes in agreements, regulatory environments, and market dynamics. (Powered by AI)